FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion
Executive Summary
Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.
You may also be interested in...
Exec Chat: Tandem CEO Sheridan On Coming Mobi Pump, New Algorithms, And Taking Share From Medtronic
In this second of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO John Sheridan provides a tour of Tandem’s next-gen innovations and the competitive landscape.
Minute Insight: CMS Expands Medicare Coverage For CGM
The new policy expands coverage to more Medicare beneficiaries using insulin to treat diabetes, as well as people who need help managing hypoglycemia, and removes the prior requirement of multiple daily insulin injections.
Tandem’s CSO Speaks On Insulin Pump Development And Its Challenges
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.